𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma

✍ Scribed by Theodore A. Braich; Sydney E. Salmon; Aurelia Robertone; David S. Alberts; Stephen E. Jones; Thomas P. Miller; Harinder S. Garewal

Publisher
Springer US
Year
1986
Tongue
English
Weight
410 KB
Volume
4
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of esorubicin (4′deoxydox
Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer
✍ James R. Rigas; Mark G. Kris; Richard J. Gralla; Robert T. Heelan; Linda D. Mark 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 264 KB

Esorubicin (4'-deoxydoxorubicin or DxDx) is an analog of doxorubicin with preclinical antitumor activity and no significant cardiotoxicity in model systems. Eleven patients with small cell lung cancer who had previously received chemotherapy were given esorubicin (25 mg/m 2 intravenously) every 3 we

Incidence of brain metastases in a cohor
Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma
✍ Leo J. Schouten; Joost Rutten; Hans A. M. Huveneers; Albert Twijnstra 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

## Abstract ## BACKGROUND The objective of this study was to report on the incidence of and factors related to the occurrence of central nervous system metastases in a cohort of patients who were diagnosed with colorectal, lung, breast, or kidney carcinoma or melanoma. ## METHODS Using the popul

Methotrexate, vinblastine, doxorubicin,
Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the hoosier oncology group
✍ Bruce J. Roth; George W. Sledge Jr; Stephen D. Williams; Steven C. Meyer; Rafat 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 490 KB 👁 2 views

Forty-six eligible patients with metastatic breast cancer (MBC) were treated with a combination of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) as first-line chemotherapy. Of 44 patients evaluable for response, 28 (64%) had an objective response, including seven (16%) who had a comp

Platinum-based combination chemotherapy
Platinum-based combination chemotherapy in advanced non-small cell lung cancer: A randomized phase II trial of the cancer and leukemia group B
✍ Green, Mark R. ;Kramar, Andrew ;Schilsky, Richard ;Stoopler, Marc ;Zimmer, Bonni 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 504 KB

## Abstract The Cancer and Leukemia Group B (CALGB) utilized a randomized phase II trial design to evaluate two cisplatin‐based combinations, cisplatin‐cytarabine (ara‐C) and cisplatin‐vinblastine, in 151 patients with advanced non‐small cell lung cancer. Patients entered on study had not received